Influence of Hydroxyehtyl Starch (HES) on Hemorehology, Coagulation and Elimination Kinetics
Stroke Patients Presenting Within 24 Hrs of Onset of Symptoms
Drug: HES administration
Drug: Hydroxy Ethyl Starch administration to stroke patients
|Study Design:||Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Primary Purpose: Treatment
|Official Title:||Clinical Trial to Study the Effects of HES on Coagulation, Hemorehology and Kinetics Comparing Two Different Products.|
- Patients discharged from hospital
- Coagulation, rehology and kinetics measurements.
|Study Start Date:||October 2005|
|Estimated Study Completion Date:||March 2006|
Patients with stroke benefit with hemodilution when administered HES in a window period and continued for a period of 10 days. Hemodilution improves the hemorheology and thus possibly preserves the cerebral tissues in the penumbra regions of affected vessels.
We propose to see the effects of prolonged administration of HES from different makes and study the kinetics, hemorehology and coagulation parameters by TEG as there is no literature on kinetics and coagulation follwing prolonged use in stroke patients and also study their neurological outcomes.
Patients presenting to the Emergency department or outpatient department within 24 hrs of manifestation of symptoms will be recruited to the study after taking informed consent in a language the patients/ family understand by the study personnel identified and authorized to do the same.
The patients will then be randomly allocated to receive HES of either make for 10 day with 10 patients in each group.
The randomization is by random number generation by computer.
The product is blinded to the patient and observer by black cover with only the label A OR B of each group.
Blood Samples will be drawn at time of randomization, after 3, 5 and 10 days for rehological, coagulation effects and kinetics of HES, stored as per requirements and analyzed. Routine biochemical tests as prescribed by the physician will be undertaken as required.
Satistical analysis of data will be done by SPSS.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00255957
|Principal Investigator:||Ramachandran Gopinath, MD,DA,FFARCSI||NIZAM'S INSTITUTE OF MEDICAL SCIENCES, PANJAGUTTA, HYDERABAD, INDIA|